59.76
전일 마감가:
$59.67
열려 있는:
$59.58
하루 거래량:
1.88M
Relative Volume:
0.92
시가총액:
$11.46B
수익:
$2.95B
순이익/손실:
$523.88M
주가수익비율:
22.22
EPS:
2.69
순현금흐름:
$620.18M
1주 성능:
+2.38%
1개월 성능:
+9.27%
6개월 성능:
-3.19%
1년 성능:
-29.39%
바이오마린 Stock (BMRN) Company Profile
명칭
Biomarin Pharmaceutical Inc
전화
(415) 506-6700
주소
105 DIGITAL DRIVE, NOVATO, CA
BMRN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
BMRN
Biomarin Pharmaceutical Inc
|
59.76 | 11.44B | 2.95B | 523.88M | 620.18M | 2.69 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
바이오마린 Stock (BMRN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-03 | 재개 | Morgan Stanley | Overweight |
2025-02-24 | 업그레이드 | Oppenheimer | Perform → Outperform |
2024-11-15 | 개시 | Wolfe Research | Outperform |
2024-10-30 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2024-10-10 | 재개 | Raymond James | Outperform |
2024-08-20 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
2024-05-17 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2024-05-14 | 개시 | Evercore ISI | Outperform |
2023-11-15 | 개시 | Wells Fargo | Overweight |
2023-10-23 | 업그레이드 | Bernstein | Underperform → Mkt Perform |
2023-09-28 | 개시 | Raymond James | Mkt Perform |
2023-09-18 | 개시 | UBS | Buy |
2023-07-27 | 개시 | Scotiabank | Sector Perform |
2023-07-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2023-06-14 | 재개 | Credit Suisse | Outperform |
2023-03-21 | 개시 | Bernstein | Underperform |
2023-02-22 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2023-02-21 | 개시 | Citigroup | Neutral |
2023-01-30 | 개시 | BMO Capital Markets | Market Perform |
2023-01-18 | 개시 | Canaccord Genuity | Hold |
2022-10-31 | 업그레이드 | Oppenheimer | Perform → Outperform |
2022-07-13 | 개시 | Cantor Fitzgerald | Overweight |
2022-06-13 | 재개 | Wedbush | Neutral |
2022-04-25 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2021-11-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2021-10-07 | 재개 | Jefferies | Buy |
2021-09-09 | 업그레이드 | Stifel | Hold → Buy |
2021-06-04 | 재개 | Robert W. Baird | Outperform |
2021-04-26 | 재개 | Credit Suisse | Outperform |
2021-03-04 | 재개 | Guggenheim | Buy |
2021-03-01 | 업그레이드 | Evercore ISI | In-line → Outperform |
2020-08-20 | 다운그레이드 | Citigroup | Buy → Neutral |
2020-08-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2020-08-19 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2020-08-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2020-08-19 | 다운그레이드 | Stifel | Buy → Hold |
2020-07-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-07-06 | 재확인 | Citigroup | Buy |
2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
2020-01-24 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2019-11-27 | 업그레이드 | Barclays | Equal Weight → Overweight |
2019-11-12 | 개시 | SunTrust | Buy |
2019-10-17 | 재개 | BofA/Merrill | Buy |
2019-05-23 | 재개 | Citigroup | Buy |
2019-04-09 | 재개 | Raymond James | Outperform |
2019-01-02 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
2018-12-14 | 개시 | Wolfe Research | Outperform |
2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
2018-08-07 | 재확인 | Stifel | Buy |
2018-08-03 | 재확인 | Stifel | Buy |
모두보기
바이오마린 주식(BMRN)의 최신 뉴스
BioMarin’s BMN 349: A Promising Step in Genetic Lung Condition Treatment - TipRanks
What analysts say about BioMarin Pharmaceutical Inc. stockConsistently superior profits - PrintWeekIndia
What drives BioMarin Pharmaceutical Inc. stock priceFree Predictions - PrintWeekIndia
What risks could impact BioMarin Pharmaceutical Inc. stock performanceRapid wealth creation - jammulinksnews.com
Will BioMarin Pharmaceutical Inc. stock benefit from AI tech trendsFree Consultation - jammulinksnews.com
BioMarin to Host Second Quarter 2025 Financial Results Conference Call and Webcast on Monday, August 4, 2025, at 4:30pm ET - Eastern Progress
BioMarin: Less Likely M&A Target As New Rival For Best-Selling Drug Emerges (Rating Downgrade) - Seeking Alpha
BioMarin Pharmaceutical Inc. Stock Analysis and ForecastOutstanding growth strategies - Autocar Professional
Is BioMarin Pharmaceutical Inc. a good long term investmentBreakthrough financial growth - jammulinksnews.com
Investors Still Waiting For A Pull Back In BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - simplywall.st
BioMarin Bets On Growth, But Competition Keeps Pressure On - Finimize
BioMarin’s BMN 349 Study: A Potential Game-Changer in Genetic Disorder Treatment - TipRanks
Morgan Stanley Sees Rebound Potential in BioMarin (BMRN), Highlights Underappreciated Voxzogo Upside - Yahoo
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt? - 富途牛牛
Looking for a Growth Stock? 3 Reasons Why BioMarin (BMRN) is a Solid Choice - Yahoo Finance
Wall Street Analysts Think BioMarin (BMRN) Could Surge 70.77%: Read This Before Placing a Bet - Zacks Investment Research
BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition By Investing.com - Investing.com South Africa
BioMarin stock maintains Outperform rating at Wolfe Research amid PKU market competition - Investing.com Nigeria
What makes BioMarin Pharmaceutical Inc. stock price move sharplyFree Step-by-Step Investment Guide - beatles.ru
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - NewsBreak: Local News & Alerts
Unpacking Q1 Earnings: BioMarin Pharmaceutical (NASDAQ:BMRN) In The Context Of Other Therapeutics Stocks - Yahoo Finance
BioMarin Pharmaceutical (BMRN) Finalizes the Acquisition of Inozyme Pharma - MSN
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - MSN
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - sharewise.com
Will BioMarin (BMRN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
10 Best Growth Stocks to Buy With Huge Upside Potential - Insider Monkey
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Momentum Stock - Yahoo Finance
BioMarin’s BMN 349 Study: A New Frontier in Genetic Mutation Treatment - TipRanks
BioMarin stock rating initiated at Overweight by Morgan Stanley on Voxzogo growth - Investing.com
The Best Biotech Stocks to Buy - Morningstar
BioMarin Pharmaceutical completes acquisition of Inozyme Pharma - grafa.com
BioMarin Pharmaceutical Closes Acquisition of Inozyme Pharma - MarketScreener
바이오마린 (BMRN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):